CMHC to highlight latest updates, research in cardiometabolic medicine
Click Here to Manage Email Alerts
The 2022 Cardiometabolic Health Congress will return in-person to Boston with the latest updates spanning all aspects of cardiometabolic health, including CVD, diabetes, kidney disease, lipid and lifestyle management and obesity.
Now in its 17th year, the Cardiometabolic Health Congress (CMHC) will take place from Oct. 19 to 22 at the Boston Park Plaza Hotel, highlighting “the present and future” of cardiometabolic health advances.
“CMHC provides up to date, evidence-based recommendations for clinical practice,” Robert H. Eckel, MD, emeritus professor of medicine in the divisions of cardiology and endocrinology, diabetes and metabolism, former professor of physiology and biophysics, and Charles A. Boettcher II Chair in Atherosclerosis at the University of Colorado Anschutz Medical Campus, and a CMHC co-chair, told Healio. “These are take-home messages that people that attend can apply to their practices on Monday.”
The conference will begin with a special daylong pre-conference Wednesday dedicated to cardiometabolic health in older adults, touching on gaps, best practices and expert perspectives. Topics includes assessing frailty in clinical practice with Jeff D. Williamson, MD, older adults and hypertension with Dena Rifkin, MD, lipid lowering therapy in older adults and guidance on polypharmacy and “deprescribing” for older adults with type 2 diabetes and CVD, featuring Marie E. McDonnell, MD, and Joseph Saseen, PharmDDonald M. Lloyd-Jones, MD, will open the pre-conference with a talk on healthy aging and cardiometabolic risk.
“The decision for this [topic] as a pre-conference topic was unanimous,” Eckel said in an interview. “These are issues that come up all the time in the practice of primary care and family medicine — decisions about lipid lowering, antihypertensives and diabetes control, and how they relate to managing health care in the older population. I am pleased that Dr. Lloyd-Jones will give the keynote talk on healthy aging and cardiometabolic risk.”
The CMHC agenda includes several other highlights:
- One of the most popular sessions every year is the annual Late-Breaking Clinical Trials and FDA Update, taking place Thursday at 8:15 a.m. and now expanded to a 2-hour session, Eckel said. The session features multiple experts highlighting the latest key trial outcomes data in diabetes, lipids, hypertension, HF, obesity, lifestyle management and chronic kidney disease.
- Louis Philipson, MD, PhD, will give the keynote address on therapeutic inertia in cardiometabolic disease on Thursday at 10:15 a.m. “This is something that really impacts practice,” Eckel said. “The idea of waiting for 6 months for the next HbA1c or lipid panel to make an important improvement related to LDL lowering and glycemic control is just too long. We are too delayed taking steps to control LDL, diabetes and BP to evidence-based goals. It is crucial to bring this concept to the attention to the clinicians who are in the trenches with patients.”
- Attendees often request more information on lifestyle management, which is reflected on the agenda of this year’s conference, Eckel said. A session on Thursday afternoon will be devoted to obesity and lifestyle, including sessions on physical activity and cardiometabolic health with Jill Kanaley, PhD, healthy eating patterns with Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES, a session on “pre-obesity” with Michelle Look, MD, and more. “There are so many controversies about what diet someone should be on,” Eckel said. “There are also concerns about how much sleep is needed, which has become increasingly relevant with the American Heart Association’s updated Life’s Essential 8.”
- Friday morning sessions will focus on dyslipidemia, atherosclerosis and thrombosis, with topics devoted to imaging modalities to assess CVD risk with Michael Blaha, MD, defining and quantifying residual atherosclerotic CVD risk in 2022 with Erin D. Michos, MD, the “evolving story” of lipoprotein(a) with Patrick Moriarty, MD, and more. Friday afternoon will feature topics devoted to diabetes management, including sessions on continuous glucose monitoring in type 2 diabetes with Irl B. Hirsch, MD, emerging treatments for diabetes with Juan P. Frias, MD, and nutrition and diets in diabetes with Alison B. Evert, MD, RDN, CDCES.
- Saturday sessions will highlight developments in the cardiorenal space, with talks on the advent of pillar therapy in kidney disease with George L. Bakris, MD, challenges and advances in HF management with Alanna A. Morris, MD, and nonsteroidal mineralocorticoid receptor antagonists for diabetic kidney disease and beyond with Rajiv Agarwal, MD.
“There are other elements that really enhance this meeting, including exhibit halls where attendees can learn more from the various companies, but moreover, there is time to meet the faculty individually during the session breaks,” Eckel said. “Also, the case discussions at this conference make this event real-time in terms of trying to approach problematic aspects that occur in cardiometabolic medicine.”
Healio will be on site providing the latest news from CMHC, with coverage of the sessions, video interviews with faculty and more. Coverage can be read here.
Reference:
17th Annual Cardiometabolic Health Congress. www.cardiometabolichealth.org/17th-annual-cmhc-2022/. Accessed on Oct. 17, 2022.
Collapse
Read more about
Click Here to Manage Email Alerts